GGrantIndex
← Search

Leveraging large language models and knowledge graphs on clinical, pathological, and sequencing data to inform precision cancer therapy

$299,999P30FY2023CANIH

Sloan-Kettering Inst Can Research, New York NY

Investigators

Linked publications, trials & patents

Trial NCT03699631Trial NCT02595918Trial NCT02417701Trial NCT02219737Trial NCT02152995Trial NCT01979523Trial NCT01947023Trial NCT01902160Trial NCT01705340Trial NCT01643278Trial NCT01638546Trial NCT01587352Trial NCT01585805Trial NCT01326702Trial NCT01281865Trial NCT01196416Trial NCT01154452Trial NCT01143402Trial NCT01119599Trial NCT01051557Trial NCT01026623Trial NCT01016015Trial NCT00957905Trial NCT00866177Trial NCT00729157Trial NCT00639509Trial NCT00601692Trial NCT00589472Trial NCT00570401Trial NCT00567229Trial NCT00550628Trial NCT00541034Trial NCT00528450Trial NCT00522301Trial NCT00521014Trial NCT00519974Trial NCT00514254Trial NCT00498927Trial NCT00483678Trial NCT00474994Trial NCT00471679Trial NCT00471601Trial NCT00470574Trial NCT00470470Trial NCT00462982Trial NCT00462501Trial NCT00459875Trial NCT00458705Trial NCT00453310Trial NCT00450827Trial NCT00416351Trial NCT00404365Trial NCT00398138Trial NCT00397904Trial NCT00369174Trial NCT00354679Trial NCT00334893Trial NCT00324480Trial NCT00245102Trial NCT00104845Trial NCT00090337Trial NCT00089245Trial NCT00087009Trial NCT00072345Trial NCT00072319Trial NCT00070057Trial NCT00067015Trial NCT00062374Trial NCT00059891Trial NCT00058253Trial NCT00054132Trial NCT00046917Trial NCT00040898Trial NCT00040872Trial NCT00039286Trial NCT00037011Trial NCT00036933Trial NCT00028730Trial NCT00024258Trial NCT00023764Trial NCT00020891Trial NCT00016146Trial NCT00014534Trial NCT00014469Trial NCT00008294Trial NCT00008242Trial NCT00006044Trial NCT00004245Trial NCT00004066Trial NCT00003923Trial NCT00003819Trial NCT00003173Trial NCT00003023Trial NCT00002981Trial NCT00002930Trial NCT00002766Trial NCT00002738Trial NCT00002718Trial NCT00002663Trial NCT00002558

Abstract

Project Summary: Precision medicine and targeted therapy are emerging domains in cancer biology that aim to incorporate individual-level clinical, pathological and genomic profiles to tailor treatment strategies for cancer patients. Several precision oncology knowledge bases, like OncoKB, My Cancer Genome, have been established to democratize clinical decision-making by leveraging expert curation of biological and clinical significance of alterations using publicly available resources. These knowledge bases, while extremely powerful, have their limitations, including the scope of annotated genes and alterations, as well as identifying precise therapies for specific combinations of a patient's genomic and clinical profiles. In this proposal, we plan to develop new computational methodologies that will integrate (i) the broad range of implicit cancer knowledge accrued by Large Language Models (LLMs) with (ii) the explicit structured clinical, pathological, and genomic knowledge derived from cancer patients in the Memorial Sloan Kettering Cancer Center’s (MSKCC) Clinical Sequencing cohort and AACR Project GENIE cohort. This will further be reinforced by expert curation, with the aim to predict combinations of genomic alterations and clinical or pathological profiles that can be matched to a specific cancer therapy. The goal of this research is to develop computational models fundamentally anchored around knowledge graphs and LLMs to bridge the gap between clinical and functional risk factors of cancer and cancer therapeutics, and to inform and enhance personalized therapies. The first aim of this proposal is to develop a knowledge graph, MSK-CancerKG, based on patient-specific clinical, pathological, and genomic alteration information from more than 100,000 patients from the MSKCC Clinical Sequencing Cohort and the AACR GENIE Project cohort. This multi-relational knowledge graph will integrate a wide spectrum of clinical features associated with each patient, abstracted features from pathological reports corresponding to the patient-derived tumor samples, along with comprehensive characterization of genomic alterations and the implicated genes. The second aim will be geared towards the fine-tuning of pre-trained Large Language Models (LLMs) using the structured, detailed and more reliable cancer-specific knowledge from MSK- CancerKG. We will meticulously benchmark these fine-tuned models against 4 state-of-the art pre-trained language models, ultimately deriving an optimized combined predictive model, coined MSK-CancerLLM. The benchmarking step will include successful clinical, alteration and treatment prediction accuracy on held-out patient data. The third aim of the proposal will be to further fine-tune MSK-CancerLLM using clinical practice guidelines and feedback to model output from cancer domain experts. The resulting model will be integrated into an AI chatbot, called MSK-Assistant, to facilitate seamless integration and interaction between the backend model and a frontend chatbot interface. Like the ChatGPT application, this will allow the research community to query about cancer biology and personalized drug recommendations and therapeutic interventions.

View original record on NIH RePORTER →